[This corrects the article DOI: 10.1371/journal.pone.0212989.].
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459474 | PMC |
| http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0215491 | PLOS |
Publication Analysis
Top Keywords
Similar Publications
Gut Immunomodulation with Vedolizumab prior to Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients with Inflammatory Bowel Disease.
Transplant Cell Ther
May 2024
Division of Hematology/Oncology, Blood and Marrow Transplant/Cellular Therapy, Hospital for Sick Children, Toronto, Ontario, Canada.
Inborn errors of immunity (IEI) are often associated with inflammatory bowel disease (IBD). IEI can be corrected by allogeneic hematopoietic stem cell transplantation (HSCT); however, peritransplantation intestinal inflammation may increase the risk of gut graft-versus-host disease (GVHD). Vedolizumab inhibits the homing of lymphocytes to the intestine and may attenuate gut GVHD, yet its role in preventing GVHD in pediatric patients with IEI-associated IBD has not been studied.
View Article and Find Full Text PDFOutcomes in Adult Inflammatory Bowel Disease Clinical Trials: Assessment of Similarity Among Participants with Adolescent-onset and Adult-onset Disease.
J Crohns Colitis
August 2024
Child Health Innovation Leadership Department, Johnson & Johnson, New Brunswick, NJ, USA.
Article Synopsis
- Most studies on pediatric inflammatory bowel disease (IBD) largely involve adolescents and suggest that adolescent-onset IBD may not differ significantly from adult-onset IBD, challenging the need for delayed drug access for adolescents.
- Researchers analyzed data from 11 randomized clinical trials, focusing on the treatment responses of 6283 participants (both adolescents and adults) to various biologics for Crohn's disease and ulcerative colitis.
- The findings indicate that treatment responses in adolescents are generally similar to those in adults, supporting the idea that efficacy data from adult studies can be used to approve drugs for adolescents more quickly.
Adverse Events and Compliance Among Inflammatory Bowel Disease Patients Treated With Home- vs Office-Based Biologic Infusions.
Inflamm Bowel Dis
September 2024
Division of Gastroenterology and Hepatology, Thomas Jefferson University Hospital, Philadelphia, PA, USA.
Background: Biologic medications are a common therapy for those with inflammatory bowel disease (IBD). There are limited data on the outcomes of home-based biologic infusions for patients with IBD. The aim of this study was to compare the safety and efficacy of biologic infusions for IBD patients who receive either home- or office-based administration.
View Article and Find Full Text PDFReal-World Effectiveness of Vedolizumab vs Anti-TNF in Biologic-naïve Crohn's Disease Patients: A 2-year Propensity-score-adjusted Analysis from the VEDOIBD-Study.
Inflamm Bowel Dis
May 2024
Clinic of General Internal Medicine I, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
Background: The aim of this observational, real-world evidence, modified intention-to-treat (mITT) study based on prospectively collected data from the VEDOIBD registry was to compare the effectiveness of vedolizumab (VEDO) vs antitumor necrosis factor (anti-TNF) in biologic-naïve Crohn's disease (CD) patients.
Methods: Between 2017 and 2020, 557 CD patients starting therapy with VEDO or anti-TNF were consecutively enrolled in 45 IBD centers across Germany. Per study protocol, the analysis excluded biologic-experienced patients and those with a missing Harvey-Bradshaw Index score, resulting in a final sample of 327 biologic-naïve CD patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!